Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Final results of a randomized clinical trial from the Italian Sarcoma Group, the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG), and the Polish Sarcoma Group (PSG).

Alessandro Gronchi,Emanuela Palmerini,Vittorio Quagliuolo,Javier Martin Broto,Antonio Lopez-Pousa,Giovanni Grignani,Antonella Brunello,Jean-Yves Blay,Robert Diaz Beveridge,Virginia Ferraresi,Iwona Lugowska,Franco Domenico Merlo,Valeria Fontana,Elena Palassini,Carlo Morosi,Silvia Stacchiotti,Angelo Paolo Dei Tos,Piero Picci,Paolo Bruzzi,Paolo G. Casali

Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Final results of a randomized clinical trial from the Italian Sarcoma Group, the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG), and the Polish Sarcoma Group (PSG).

2019

11000Background: A ISG randomized trial on 5 cycles of adjuvant epirubicin+ifosfamide (EI) versus no chemotherapy suggested an OS benefit in localized high-risk STS (JCO 2001;19:1238). A subsequent...

Keywords:

Pathology
Epirubicin
Oncology
Ifosfamide
Randomized controlled trial
Sarcoma
Medicine
Internal medicine
Soft tissue
Adjuvant
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations